what is the average weight loss with tirzepatide for Medical Tirzepatide is a New Medication

Benefits: Significant reduction in visceral (belly) fat Improved insulin sensitivity Increased lean mass Better lipid profiles Dosing: 1-2mg subcutaneous daily Best for: Men with significant visceral fat, metabolic syndrome, insulin resistance

Copper Peptide Evidence Evidence for copper peptides is more limited but targeted

PubMed laboratory research record [PMID: 36803633] PubMed record related to this compound for laboratory literature review

In comparison, a major study on tirzepatide found people who took the medication for 72 weeks lost an average of 20.9% of their body weight

However, its important to note that the effectiveness of Wegovy in reducing belly fat can vary from individual to individual

Kidney Issues Some patients may develop kidney problems, including acute kidney injury, particularly if they experience significant dehydration due to side effects like nausea, vomiting, or diarrhoea